Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- IMS Japan VP Miyoshi Calls for Focus Shift from Long-Listed Products to Abolishment of Post-Market Expansion Re-Pricing
February 29, 2012
- Major European, US Drug Makers Turning Sights Toward “Mini-buster” Drugs for Rare Diseases
February 29, 2012
- OTS102 Fails to Prolong Survival in Pancreatic Cancer: OncoTherapy Science
February 29, 2012
- Wakamoto to Comarket Bausch & Lomb’s Ocuvite Series of Eye Supplements from April 1
February 29, 2012
- Sanofi Pasteur Files for Approval for Monovalent IPV
February 27, 2012
- Novartis Pharma Submits Afinitor for Add’l Indication of Tuberous Sclerosis
February 27, 2012
- EMA Accepts MAA for Peginesatide for Treatment of Anemia Associated with CKD: Takeda
February 27, 2012
- JCR Pharmaceuticals Announces Favorable Results from PI/II Trial of Stem-cell-based Therapy
February 27, 2012
- Diabetes Treatments: Their Development and Market (2)
February 27, 2012
- Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
- Nichi-Iko and Pfizer Japan Obtain Approval for Cisplatin Generic for Indication of Biliary Tract Cancer
February 24, 2012
- Ajinomoto Pharm. Files NDA for New Oral Bowel Cleansing Agent in Japan
February 24, 2012
- SymBio’s Licensee InnoPharmax Launches Bendamustine in Taiwan
February 24, 2012
- Eli Lilly Receives Approval for Zyprexa, First for Depression in Bipolar Disorder
February 23, 2012
- Use of Rasilez in Combination with ACE Inhibitors, ARBs in Patients with Diabetes to Be Contraindicated in Europe: Novartis
February 23, 2012
- RaQualia Maintains Focus on Pain, GI Diseases in New Midterm Management Plan
February 23, 2012
- Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
- Takeda’s Ulcerative Colitis Treatment Vedolizumab Shows Significant Improvement and Remission in Global PIII Trial
February 22, 2012
- CMIC HD Files NDA for UCD Treatment in Japan
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…